Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445484 | 0.94 | NOD1 (0.46) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL2545697 | 0.93 | NOD1 (0.48) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL30830405 | 0.93 | NOD1 (0.48) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL2545708 | 0.93 | NOD1 (0.48) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL10704006 | 0.87 | NOD1 (0.44) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL28610885 | 0.86 | SLC7A5 (0.50) | NOD1ITGB1ITGA4SLC7A5SLC1A3 | |
| SCHEMBL10621766 | 0.83 | NOD1 (0.37) | NOD1ITGB1ITGA4ACEKIF11 | |
| N-Monoacetylcystine SCHEMBL111494 | 0.83 | MAPT (0.48) | NOD1ITGB1ITGA4NOS2NOS1 | |
| N-Monoacetylcystine SCHEMBL20816351 | 0.83 | MAPT (0.48) | NOD1ITGB1ITGA4NOS2NOS1 | |
| N-Monoacetylcystine SCHEMBL468824 | 0.83 | MAPT (0.48) | NOD1ITGB1ITGA4NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| EP-2925771-B1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL SCIENT IND RES (IN) | 2021-08-18 | — | — | EP | disclosed |
| US-9751911-B2 | Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-09-05 | — | — | US | disclosed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | disclosed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | disclosed |
| EP-0399656-B1 | Nutrient compositions for amino acid supplementation in mammals | KYOWA HAKKO KOGYO KK (JP) | 1994-02-02 | — | — | EP | disclosed |
| US-5102871-A | Admistering glutamy-cystine and or glutamyl-cysteine disulfide to a mammal to increase in vivo level of cysteine | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-4968696-A | CHRONIC UREMIA OR HEPATIC CIRRHOSIS | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH + CO. KG (DE) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | NOD1 269/4885ITGB1 2816/4885ITGA4 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.